Russian firm gets approval for drug said to block coronavirus replication

Russian firm gets approval for drug said to block coronavirus replication
Russian firm gets approval for drug said to block coronavirus replication

Thank you for reading the news about Russian firm gets approval for drug said to block coronavirus replication and now with the details

Aden - Yasmine El Tohamy - R-Pharm says Coronavir doesn't just treat complications of Covid-19 but battles the virus itself.

Russia has approved a new anti-viral drug, Coronavir, to treat Covid-19 patients, its developer R-Pharm said on Wednesday, as Russia's tally of infections hit 700,000.

It said a clinical trial involving mild or medium-level cases had shown the drug to be highly effective in inhibiting replication of the new coronavirus.

"Coronavir is one of the first drugs in Russia and in the world that does not tackle the complications caused by SARS-CoV-2, but battles the virus itself," the company's statement said.

It said a clinical study showed improvement in 55 per cent of outpatient cases on the seventh day of treatment with Coronavir, against 20 per cent of those with standard etiotropic therapy - meaning treatment of cause rather than symptoms. R-Pharm said there was also a significant difference at 14 days.

By the fifth day of treatment, the novel coronavirus had been eliminated in 77.5 per cent of patients who took the drug, R-Pharm said.

"Global clinical practice and the clinical study we conducted have confirmed that Coronavir puts a much more rapid stop to the infection as a result of its effective obstruction of the virus's replication," Mikhail Samsonov, R-Pharm's medical director, was cited as saying.

Testing began in late May and over 110 outpatients have now received the treatment, the head of clinical trials at Russia's Central Research Institute of Epidemiology, Tatyana Ryzhentsova, was cited as saying.

The drug is the third registered in Russia to treat the new coronavirus. The first, Avifavir, has been given to patients since June 11.

The health ministry gave its approval for Avifavir's use under an accelerated process while clinical trials, held over a shorter period and with fewer people than in many other countries, were still under way.

In a statement on Wednesday, Russia's RDIF sovereign wealth fund, which provided financial backing for Avifavir, said it had asked the ministry to approve the drug for use by patients treating Covid-19 at home.

It said second- and third-phase clinical trials, as well as data from the first month of hospital use, had demonstrated positive results when Avifavir was used in the early and middle stages of the illness.

Russia's official nationwide case tally stood at 700,792 as of Wednesday, with 10,667 deaths.

These were the details of the news Russian firm gets approval for drug said to block coronavirus replication for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Khaleej Times and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV China wants ‘unpredictable’ Trump to lose election, says US intelligence
NEXT British MP Craig Whittaker accused of racism after blaming Muslims and minorities for new coronavirus lockdown